Bolaños CA, Quesada AA

Language: Spanish
References: 21
Page: 168-175
PDF size: 348.17 Kb.

ABSTRACT

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low number of circulating platelets. Severe thrombocytopenia may jeopardize the patient’s life, so it is important to know the treatment options for establishing it properly and quickly. There is a subject of debate among pediatric hematologists, regarding the initiation of pharmacological treatment or expectant treatment. This review provides diagnostic clues and lists the available treatments for the different ITP forms in children, as well as for handling emergencies.

REFERENCES

1. Al-Mulla N, Bener A, Amer A, Abu-Laban M. Idiopathic thrombocytopenic purpura in childhood: a population-based study in Qatar. J Pediatr (Rio J). 2009; 85(3): 269-272.

2. Bilhartz J, Howle E, Walkovich K. Evaluation, Diagnosis & Management of Immune Thrombocytopenia. Hematology Chapter B, University of Michigan Pediatric Heme/Onc Program 2010: 1-10.

3. Blanchette V, Bolton-Maggs P. Childhood Immune Thrombocytopenic Purpura: Diagnosis and Management. Hematol Oncol Clin N Am 2010; 24: 249–273.

4. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007; 110(10): 3526-3531.

5. Burzynski J. New options after first-line therapy for chronic immune thrombocytopenic purpura. Am J Health-Syst Pharm 2009; 66(2): S11-S21.

6. Bussel J. Traditional and New Approaches to the Managemement of Immune Thrombocytopenia: Issues of When and Who to Treat. Hematol Oncol Clin N Am 2009; 23: 1329–1341.

7. Cines D, Bussel JB, Liebman HA Prak L. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113(26):6511-6521.

8. De Mattia D, Del Príncipe D, Del Vechio G. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Haematologica 2000; 85(4): 420-424.

9. Donato H, Cedola A, Elena G. Guideline for dia gnosis and treatment of immune thrombocytopenia. Arch Argent Pediatr 2010; 108(2):173-178.

10. González O. Púrpura Trombocitopénica Inmunológica en el Niño. Medicina universitaria 2003; 5(19): 110-6.

11. Indiana Hemophilia & Thrombosis Center. Immune Thrombocytopenic Purpura (ITP): A New Look at an Old Disorder. Blood Type 2010; 1-6.

12. Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009; 373:1562–69.

13. Pruemer J. Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. Am J Health-Syst Pharm 2009; 66(2):S4-S10.

14. Psaila B, Bussel J. Immune Thrombocytopenic Purpura. Hematol Oncol Clin N Am 2007; 21: 743–759.

15. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113(11): 2386-2393.

16. Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Reviews 2002; 00: 1–4.

17. Sequeira LA. Púrpura Trombocitopénica Autoinmune (Caso Clínico y Revisión Bibliográfica). Revista Médica de Costa Rica y Centroamérica 2008; LXV (582): 9-13.

18. Silverman M. Purpura. Emergency Medicine, Hematology and Oncology. Emedicine June 2010. http://emedicine.medscape.com/article/779545-overview. Consultada 8 de noviembre de 2010.

19. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113(6): 1231-1240.

20. Taube T Schmid H, Reinhard H, vonStackelberg A, Henze G, Schulte U. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. haematologica 2005; 90(2):281-283.

21. Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90(1):72-77.